Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | NR3C2 | P08235 | 8/20 | 0.46 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.42 |
| ▸ | CCNC | P24863 | 2/20 | 0.41 |
| ▸ | CDK8 | P49336 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.40 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2961287 | 0.84 | FFAR1 (0.64) | FFAR1 | |
| SCHEMBL4596387 | 0.84 | FFAR1 (0.49) | FFAR1NR3C2KMT2AKCNQ2UHRF1 | |
| SCHEMBL8567027 | 0.82 | GABRP (0.47) | NR3C2CCNCCDK8KMT2APIK3CB | |
| SCHEMBL23015824 | 0.81 | CYP1A2 (0.50) | NR3C2CAPN1ALDH1A1LMNAAURKA | |
| SCHEMBL5361827 | 0.81 | CAPN1 (0.43) | NR3C2CAPN1SLC22A12ALDH1A1LMNA | |
| SCHEMBL29658465 | 0.81 | GABRP (0.46) | NR3C2CCNCCDK8KMT2APIK3CB | |
| SCHEMBL3129887 | 0.80 | ALDH1A1 (0.41) | NR3C2CAPN1ALDH1A1LMNAAURKA | |
| SCHEMBL3129593 | 0.79 | CAPN1 (0.42) | NR3C2CAPN1ALDH1A1LMNAAURKA | |
| SCHEMBL3129466 | 0.79 | CYP4F2 (0.42) | NR3C2CAPN1SLC22A12AURKA | |
| SCHEMBL3121398 | 0.79 | CAPN1 (0.42) | NR3C2CAPN1ALDH1A1LMNAAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018069468-A1 | BENZOTHIAZOLE DERIVATIVES AS DYRK1 INHIBITORS | PHARMASUM THERAPEUTICS AS (NO) | 2018-04-19 | — | — | WO | disclosed |
| US-20100204119-A1 | 4-AMINO-5-OXO-7,8-DIHYDROPYRIMIDO[5,4-F][1,4]OXAZEPIN-6(5H)-YL PHENYL DERIVATIVES | PFIZER INC | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204119-A1 | 4-AMINO-5-OXO-7,8-DIHYDROPYRIMIDO[5,4-F][1,4]OXAZEPIN-6(5H)-YL PHENYL DERIVATIVES | DGAT1, DGAT2, MOGAT2 | FFAR1 226/4885NR3C2 1382/4885CAPN1 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.